Prospective, Single-Center, Non-Randomized Study of the PhysioWave™ Cardiovascular Analyzer

Inclusion Criteria: * Subjects \>18 years old * Subject signs a written Informed Consent form to participate in the study, prior to any study procedures Subgroup Inclusion Criteria * Subject has been taking ACE Inhibitors or Angiotensin Receptor Blockers for at least 30 days Exclusion Criteria: * Known significant carotid or femoral artery stenosis * Non-palpable (non-detectable) arterial pulse at the sites of measurements * Pacemaker, defibrillator, or other cardiac stimulator * Erratic, accelerated or mechanically controlled irregular heart rhythm, or an arrhythmia * History of cardiac valve disorder or cardiac valve disease * History of venous disease, including venous insufficiency or deep vein thrombosis * History of peripheral artery disease * Requirement for supplemental oxygen * Neuromuscular disorders that cause shaking or tremors (such as Parkinson's disease or Multiple Sclerosis), or other disease or condition affecting balance * Amputation or malformation of any limb or extremity (foot, leg, or arm) which would impede the placement of blood pressure cuffs or standing on the scale with two feet. * Known or suspected pregnancy * Inability to provide informed consent * Mental incompetence or a prisoner status * Current participation in a clinical trial of another investigational drug or device in which the study endpoint has not been met * BMI \> 40 * Subjects \> 400 lbs * Subjects on strong vasoactive drugs, such as those used to control high blood pressure, for \<30 days * Blood loss or blood donation of ˃ 550 mL within 30 days before study procedure